TABLE 2.
Peptides containing undefined CD8+ and CD4+ T-cell epitopes in Gag p24/p17 recognized by MVA.HIVA vaccine respondersa
| Peptide and sequence | Responder subject no. | Fold increase post-MVA.HIVA |
|---|---|---|
| CD8+ peptides | ||
| KIRLRPGGKKKYRLK | 012 | 2.6 |
| MTSNPPIPVGDIYKR | 022 | 6.7 |
| VRMYSPVSILDIRQG | 022 | 3.2 |
| KDTKEALDKIEEIQN | 001 | 4.3 |
| RDYVDRFFKTLRAEQ | 005 | 23 |
| TETLLVQNANPDCKS | 005 | 18 |
| GGKLDAWEKIRLRPG | 005 | 21 |
| ERFALNPSLLE | 005 | 18 |
| CD4+ peptide sequence | ||
| PQDLNMMLNIVGGHQA | 016 | 3.4 |
| HQAAMQMLKDTINEE | 016 | 3.6 |
| GGKLDAWEKIRLRPG | 005 | 2 |
a
Postvaccination responses were defined as ≥2-fold above preimmunization values. Peptides containing published epitopes were included if they were not known to be restricted by any of the HLA alleles expressed by the vaccine responder.